Rifaximin

Generic Name: Rifaximin

Brand Names: Xifaxan, Zaxine

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₁N_₃O_₁₁

CAS Number: 80621-81-4

Unique Ingredient Identifier: L36O5T016N

Background: Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalop...

Indication: Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in ...

Associated Conditions: Bacterial Infections, Clostridium difficile infection recurrence, Hepatic Encephalopathy (HE), Irritable Bowel Syndrome (IBS), Traveler's Diarrhea

Associated Therapies: -

Clinical Trials

Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)

Phase 1

Completed

Conditions: Malignancy
Bone Marrow Transplantation

Interventions: Drug: Rifaximin

First Posted Date: 2009-08-27

Last Posted Date: 2013-11-27

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT00967096

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex

Phase 1

Conditions: Gulf War Syndrome

Interventions: Procedure: Lactulose Breath Test
Drug: Placebo
Drug: Rifaximin

First Posted Date: 2009-08-11

Last Posted Date: 2013-05-01

Lead Sponsor: Henry C. Lin, MD

Target Recruit Count: 210

Registration Number: NCT00956150

Locations: 🇺🇸
New Mexico VA Healthcare System, Albuquerque, New Mexico, United States

Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

Not Applicable

Completed

Conditions: Functional Dyspepsia
Small Intestinal Bacterial Overgrowth
Chronic Abdominal Discomfort

Interventions: Drug: Placebo
Drug: Rifaximin
Procedure: Lactulose Breath Test

First Posted Date: 2009-08-11

Last Posted Date: 2012-10-24

Lead Sponsor: Henry C. Lin, MD

Target Recruit Count: 55

Registration Number: NCT00956397

Locations: 🇺🇸
General Clinical Research Center, Albuquerque, New Mexico, United States

Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

Not Applicable

Completed

Conditions: Constipation-predominant Irritable Bowel Syndrome

Interventions: Drug: Neomycin
Drug: Placebo
Drug: Rifaximin

First Posted Date: 2009-07-24

Last Posted Date: 2015-08-10

Lead Sponsor: Mark Pimentel, MD

Target Recruit Count: 37

Registration Number: NCT00945334

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Georgia Health Sciences University, Augusta, Georgia, United States

Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea

Phase 4

Withdrawn

Conditions: Travelers' Diarrhea

Interventions: Drug: Rifaximin

First Posted Date: 2009-04-06

Last Posted Date: 2015-06-10

Lead Sponsor: The University of Texas Health Science Center, Houston

Registration Number: NCT00875875

Locations: 🇲🇽
Enteric Disease Clinic, Guadalajara, Jalisco, Mexico

Trial of Rifaximin in the Treatment of Tropical Enteropathy

Not Applicable

Completed

Conditions: Tropical Enteropathy

Interventions: Drug: Placebo
Drug: Rifaximin

First Posted Date: 2009-03-10

Last Posted Date: 2019-11-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 147

Registration Number: NCT00858988

Rifaximin Versus Lactulose in Renal Failure

Phase 4

Withdrawn

Conditions: Renal Failure
Liver Cirrhosis

Interventions: Drug: Rifaximin
Drug: Lactulose

First Posted Date: 2008-09-09

Last Posted Date: 2022-02-08

Lead Sponsor: Weill Medical College of Cornell University

Registration Number: NCT00748904

Locations: 🇺🇸
Weill Cornell Medical Center, New York, New York, United States

Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers

Phase 1

Completed

Conditions: Pharmacokinetic

Interventions: Drug: rifaximin

First Posted Date: 2008-08-29

Last Posted Date: 2019-11-29

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 24

Registration Number: NCT00743912

Rifaximin for Prevention of Travellers' Diarrhea

Phase 3

Completed

Conditions: Diarrhea

Interventions: Drug: Rifaximin
Drug: Placebo

First Posted Date: 2008-08-27

Last Posted Date: 2019-12-18

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 210

Registration Number: NCT00742469

Locations: 🇲🇽
University of San Diego, Guadalajara, Jalisco, Mexico

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

Phase 3

Completed

Conditions: Non-Constipation Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: Rifaximin

First Posted Date: 2008-08-11

Last Posted Date: 2019-11-29

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 623

Registration Number: NCT00731679

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy